TABLE 4

Sensitivity analysis efficacy variables (mITT set)a

ParameterValue
CadazolidVancomycin (125 mg QID)
250 mg BID500 mg BID1,000 mg BID
Modified clinical cure rate [n (%)]16 (94.1)18 (90.0)16 (84.2)19 (86.4)
    80% CI79.0, 99.475.5, 97.368.1, 94.172.1, 94.9
    n17201922
Modified recurrence rate [n (%)]3 (18.8)4 (22.2)5 (33.3)7 (36.8)
    80% CI7.1, 37.110.1, 39.617.2, 53.221.8, 54.1
    n16181519
Modified sustained clinical response rate [n (%)]13 (76.5)14 (70.0)10 (55.6)12 (54.5)
    80% CI58.4, 89.353.3, 83.438.0, 72.138.9, 69.5
    n17201822
Median time to modified resolution of diarrhea (h)48.060.048.072.0
    80% CI48.0, 72.048.0, 72.024.0, 96.048.0, 96.0
    n17201922
  • a The mITT analysis set included all randomized patients who received ≥1 dose of study drug and had a confirmed diagnosis of CDI (positive toxigenic culture by a central laboratory).